Incyte Corporation
Incyte Reports Third Quarter 2025 Financial Results and Business Updates
Summary
Incyte Corporation announced strong third-quarter 2025 financial results, reporting total revenues of $1.37 billion, a 20% increase year-over-year. Key highlights include a 7% increase in Jakafi net product revenue to $791 million and a 35% increase in Opzelura net product revenue to $188 million. The company also raised its full-year 2025 net product revenue guidance to $4.23 - $4.32 billion. Business updates include progress in clinical trials and regulatory submissions for various pipeline products.
Profitelligence Alerts
Get alerts for INCY
Be first to know when Incyte Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. With a focus on oncology and inflammation, Incyte aims to address significant unmet medical needs through its robust portfolio of proprietary compounds. The company's flagship product, a therapeutic for certain types of blood cancers, underscores its pivotal role in cancer treatment paradigms. Incyte also invests heavily in research and development, maintaining a pipeline of next-generation treatments in various stages of clinical trials. Having established strategic partnerships with leading global pharmaceutical companies, Incyte leverages collaborative efforts to enhance its research capabilities and market presence. Headquartered in Wilmington, Delaware, Incyte Corporation is a key player in the biopharmaceutical sector, significantly contributing to advancements in medical science and patient care through its commitment to innovation and therapeutic excellence.
Official SEC Documents
Advertisement